.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The choice of deep brain stimulation target in advanced Parkinson disease often centres on the subthalamic nucleus (STN) versus the globus pallidus internus (GPi). A randomized blinded pilot study compared the two targets in patients with levodopa-induced dyskinesia and motor fluctuations. After implantation, motor symptoms improved substantially with both stimulation sites. STN stimulation produced a greater reduction in levodopa dose, while dyskinesia improved with both approaches. The study also raised a useful clinical consideration: cognitive and behavioural complications were observed only in the STN group in this small cohort. The authors therefore cautioned against assuming that STN stimulation should replace GPi stimulation in every patient. For HCPs, target selection should be individualized according to the dominant motor problem, medication response, dyskinesia burden, cognitive profile, psychiatric history and need to reduce dopaminergic medication. GPi may be attractive when dyskinesia is a major concern or when preserving medication flexibility is important. STN may be attractive when medication reduction is a key objective. The paper remains clinically relevant because modern DBS should be planned around the patient's phenotype rather than a default target.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The choice of deep brain stimulation target in advanced Parkinson disease often centres on the subthalamic nucleus (STN) versus the globus pallidus internus (GPi). A randomized blinded pilot study compared the two targets in patients with levodopa-induced dyskinesia and motor fluctuations. After implantation, motor symptoms improved substantially with both stimulation sites. STN stimulation produced a greater reduction in levodopa dose, while dyskinesia improved with both approaches. The study also raised a useful clinical consideration: cognitive and behavioural complications were observed only in the STN group in this small cohort. The authors therefore cautioned against assuming that STN stimulation should replace GPi stimulation in every patient. For HCPs, target selection should be individualized according to the dominant motor problem, medication response, dyskinesia burden, cognitive profile, psychiatric history and need to reduce dopaminergic medication. GPi may be attractive when dyskinesia is a major concern or when preserving medication flexibility is important. STN may be attractive when medication reduction is a key objective. The paper remains clinically relevant because modern DBS should be planned around the patient's phenotype rather than a default target.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
